Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

Risky Drug Mixture Gets Riskier When 2 Different Doctors Prescri

Posted 8/18/2021

Benzodiazepines and opioids are two types of medications that act on the brain. Stress, sleeplessness, and worry episodes were treated with benzodiazepines, whereas discomfort is treated with opioids. Since both reduce the desire to breathe, individuals who use opiates and benzodiazepines at a similar moment get an increased chance of overdose.

Doctors had long cautioned about the dangers of mixing sedatives and prescribed painkillers, such as Xanax and Vicodin, Valium and Norco, or Restoril and Percocet. Recent research finds that prescribing the two distinct kinds of medicines to the same person by numerous doctors instead of the single physician is highly dangerous.

We know that having overlapping opioid and benzodiazepine prescriptions is one of the strongest risk factors for overdose. Our findings suggest that the circumstances that lead to these overlapping prescriptions matter.

External Reference: https://www.datasourcehub.com/drug-riskier-doctors-prescribe/

Back to all news

Sponsor Spotlight

COMPASS Pathways


COMPASS Pathways is delighted to be a sponsor of NASCSA and looks forward to both engaging with controlled substances authorities, NASCSA leadership, and members to learn about their important work, and educate about our company's mission and the innovations underway using novel therapies.

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

We are developing innovative therapies and, when appropriate, combining them with psychological support and next-generation digital tools to forge new, sustainable mental health care pathways.

Our investigational COMP360 psilocybin therapy is currently undergoing phase 3 investigation in treatment-resistant depression. We are also assessing COMP360 in anorexia nervosa and post-traumatic stress disorder, across multiple clinical studies.

Learn more https://www.compasspathways.com

All Sponsors